Suchergebnisse

Comparative risk assessments in the chemical safety field sometimes adopt a lofty view of the purposes of legislation. This personal essay is not lofty, and it is not just another professor's comparison of the purposes of the European Union's REACH with American regulatory programmes. I write today as an individual, as the last active remaining participant of the small group of industry players in 1975–76 who helped to negotiate the details of the 1976 US Toxic Substances Control Act ("TSCA"). As advocates for industry we won the key arguments over the law's terms and conditions, but the decades since have not shown TSCA to be a triumph for anyone.

Professor O'Reilly's study of recent drug review legislation applies a historical and holistic view of promotion practices for unapproved uses of prescription drugs. He faults Congress for moving public health protections away from a strictly protective mode and toward assistance to drug marketers. He argues that the adverse health consequences of "off-label" promotion of drugs are not well understood, and that the 1997 amendments disserved the public health interest while expanding pharmaceutical company profits.

The ceasing of a family member's ability to reason, function and respond is a tragedy. With major increases in dementia predicted for the coming decade, a book like 'Dementia and Alzheimer's' is needed ever more to cut through clutter of anecdotes and assumptions. Facing the crisis of widespread patient volumes with dementia, 'Dementia and Alzheimer's' explains governmental and private entities' benefit programs for dementia patients, and how government and insurers do and should respond, while integrating sophisticated medical tactics with vital family cooperative responses to their loved one's mental health crisis. The text explains what works and what approaches work best for responses.